Humira (adalimumab) prior authorization denied appeal
TNF inhibitor
Typical PA criteria
- Diagnosis from approved list (RA, psoriasis, Crohn's, UC, AS, JIA, HS, uveitis)
- Trial and failure of methotrexate or other conventional therapy
- Negative TB screen
Why your PA was denied
- Step therapy with biosimilar not completed
- Non-preferred brand (biosimilar preferred)
- Missing TB screen
- Indication not on plan list
Evidence that overturns the denial
- ✓Diagnosis with ICD-10 code
- ✓Conventional therapy trial history
- ✓Negative QuantiFERON or PPD
- ✓Disease activity scores (DAS28, PASI, HBI)
Most plans now require a biosimilar (Yusimry, Hadlima, Amjevita) before brand Humira. If the denial is biosimilar step therapy, switching is often faster than appealing.
Free analysis identifies the cited policy and missing evidence. Then a finished letter that maps your chart to the criteria.
FAQ
Why was my Humira (adalimumab) prior authorization denied?+
The most common reasons are: Step therapy with biosimilar not completed; Non-preferred brand (biosimilar preferred); Missing TB screen. Your denial letter names the specific criteria you did not meet.
How do I appeal a Humira (adalimumab) denial?+
File a written appeal within 180 days that cites the insurer's clinical policy, includes a letter of medical necessity from the prescriber, and documents the criteria the insurer requires.
What evidence overturns a Humira (adalimumab) denial?+
Diagnosis with ICD-10 code; Conventional therapy trial history; Negative QuantiFERON or PPD.
What if the plan excludes Humira (adalimumab) entirely?+
Plan exclusions are different from medical-necessity denials. Check the Summary Plan Description. If the drug is fully excluded, an appeal will not overturn it; you may need a formulary exception or manufacturer assistance program.
Other drugs
- Wegovy (semaglutide)
- Zepbound (tirzepatide)
- Ozempic (semaglutide)
- Mounjaro (tirzepatide)
- Saxenda (liraglutide)